The YPEL family genes are highly conserved across a diverse range of eukaryotic organisms and thus potentially involved in essential cellula
The YPEL family genes are highly conserved across a diverse range of eukaryotic organisms and thus potentially involved in essential cellular processes. Ypel4, one of five YPEL family gene orthologs in mouse and human, is highly and specifically expressed in late terminal erythroid differentiation (TED). In this study, we investigated the role of Ypel4 in murine erythropoiesis, providing for the first time an in-depth description of a Ypel4-null phenotype in vivo. We demonstrated that the Ypel4-null mice displayed a secondary polycythemia with macro- and reticulocytosis. While lack of Ypel4 did not affect steady-state TED in the bone marrow or spleen, the anemia-recovering capacity of Ypel4-null cells was diminished. Furthermore, Ypel4-null red blood cells (RBC) were cleared from the circulation at an increased rate, demonstrating an intrinsic defect of RBCs. Scanning electron micrographs revealed an ovalocytic morphology of Ypel4-null RBCs and functional testing confirmed reduced deformability. Even though Band 3 protein levels were shown to be reduced in Ypel4-null RBC membranes, we could not find support for a physical interaction between YPEL4 and the Band 3 protein. In conclusion, our findings provide crucial insights into the role of Ypel4 in preserving normal red cell membrane integrity.
Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Molecular Medicine and Gene Therapy, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för molekylärmedicin och genterapi, Originator, Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), StemTherapy: National Initiative on Stem Cells for Regenerative Therapy, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), StemTherapy: National Initiative on Stem Cells for Regenerative Therapy, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Molecular Medicine and Gene Therapy, Stem Cells to Red Blood Cells, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för molekylärmedicin och genterapi, Stamceller till röda blodkroppar, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Molecular Medicine and Gene Therapy, Stem cell and red cell biology, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för molekylärmedicin och genterapi, Stem cell and red cell biology, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Molecular Hematology (DMH), Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för molekylär hematologi, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Proteomic Hematology, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Proteomisk hematologi, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Targeted therapies in leukemia, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Målinriktade behandlingar för leukemi, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Originator
